Test Code PMSBB Postmortem Screening, Bile and Blood Spot
Reporting Name
Postmortem ScreeningPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Postmortem evaluation of individuals at any age who died suddenly or unexpectedly; testing is particularly recommended under the following circumstances (risk factors):
-Family history of sudden infant death syndrome or other sudden unexpected deaths at any age
-Family history of Reye syndrome
-Maternal complications of pregnancy (acute fatty liver pregnancy, HELLP syndrome [hemolysis, elevated liver enzymes, and low platelet count])
-Lethargy, vomiting, fasting in the 48 hours prior to death
-Allegation of child abuse (excluding obvious cases of trauma, physical harm)
Macroscopic findings at autopsy:
-Fatty infiltration of the liver
-Dilated or hypertrophic cardiomyopathy
-Autopsy evidence of infection that routinely would not represent a life-threatening event
Method Name
Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
Necessary Information
Request the original newborn screening card from the state laboratory where the decedent was born. See Request for Original Newborn Screening Card. Provide patient name, date and time of birth and death, suspected cause of death, circumstances of death, relevant family history, and date and time of sample collection.
Biochemical Genetics Patient Information (T602) is recommended, but not required, to be filled out and sent with the specimen to aid in the interpretation of test results.
Specimen Required
Both bile and blood spots are required.
Supplies: Card-Postmortem Screening (Filter Paper) (T525)
Container/Tube:
Preferred: Card-Postmortem Screening Card (Filter Paper)
Acceptable: Whatman Protein Saver 903 paper or local newborn screening card
Specimen Volume: Properly completed screening card
Collection Instructions:
1. Collect blood in a heparin-containing tube and drop 25 mcL of blood onto the 2 circles labeled Blood.
2. Collect bile by direct puncture of the gallbladder and drop 25 mcL of bile onto the 2 circles labeled Bile.
3. Allow to dry at ambient temperature in a horizontal position for a minimum of 3 hours.
4. Fill out information on page 2 of collection card.
5. Do not expose specimen to heat or direct sunlight.
6. Do not stack wet specimens.
7. Keep specimen dry.
Specimen Type
Whole bloodSpecimen Minimum Volume
Bile spot: 1; Blood spot: 1
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole blood | Ambient (preferred) | FILTER PAPER | |
Frozen | FILTER PAPER | ||
Refrigerated | FILTER PAPER |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
Quantitative results are compared to a constantly updated range which corresponds to the 5 to 95 percentile interval of all postmortem cases analyzed in our laboratory.
Interpretation
Reports of abnormal acylcarnitine profiles will include an overview of the results and of their significance, a correlation to available clinical information, possible differential diagnoses, recommendations for additional biochemical testing and confirmatory studies (enzyme assay, molecular analysis) as indicated, name and phone number of contacts who may provide these studies, and a phone number to reach one of the laboratory directors in case the referring physician has additional questions.
Abnormal results are not always sufficient to conclusively establish a diagnosis of a particular disease. To verify a preliminary diagnosis based on an acylcarnitine analysis, independent biochemical (eg, FAO / Fatty Acid Oxidation Probe Assay, Fibroblast Culture) or molecular genetic analyses are required using additional tissue such as skin fibroblasts from the deceased patient. If not available, molecular genetic analysis of a patient's parents may enable the confirmation of a diagnosis.
Day(s) Performed
Wednesday
Report Available
7 to 16 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
83789
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PMSBB | Postmortem Screening | In Process |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
22675 | Specimen | 31208-2 |
22676 | Specimen ID | 57723-9 |
22677 | Source | 31208-2 |
22678 | Order Date | 82785-7 |
22679 | Reason For Referral | 42349-1 |
22680 | Method | 85069-3 |
22684 | Results | In Process |
81931 | Interpretation | 59462-2 |
22681 | Amendment | 48767-8 |
22682 | Reviewed By | 18771-6 |
22683 | Release Date | 82772-5 |
Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.
Testing Algorithm
For more information see Postmortem Screening Algorithm for Fatty Acid Oxidation Disorders and Organic Acidurias.